H
Hiroyuki Satoh
Researcher at University of Tokyo
Publications - 12
Citations - 3307
Hiroyuki Satoh is an academic researcher from University of Tokyo. The author has contributed to research in topics: Rho kinase inhibitor & Endothelin 1. The author has an hindex of 7, co-authored 12 publications receiving 3214 citations. Previous affiliations of Hiroyuki Satoh include Mitsubishi Tanabe Pharma & Mitsubishi.
Papers
More filters
Journal ArticleDOI
Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension
Masayoshi Uehata,Toshimasa Ishizaki,Hiroyuki Satoh,Takashi Ono,Toshio Kawahara,Tamami Morishita,Hiroki Tamakawa,Keiji Yamagami,Jun Inui,Midori Maekawa,Shuh Narumiya +10 more
TL;DR: Pyridine derivative Y-27632 consistently suppresses Rho-induced, p160ROCK-mediated formation of stress fibres in cultured cells and dramatically corrects hypertension in several hypertensive rat models, suggesting that compounds that inhibit this process might be useful therapeutically.
Patent
MEDICINES COMPRISING Rho KINASE INHIBITOR
TL;DR: Novel medicines comprising Rho kinase inhibitors, such as hypertension remedy, angina remedy, cerebrovascular twitching inhibitor, asthma remedy, premature birth preventive, arteriosclerosis remedy, anticancer drug, anti-phlogistic, immunosuppressive, autoimmune disease remedy, anti AIDS drug, contraceptive, digestive infection preventive, osteoporosis remedy, retinopathy remedy, and cerebral function ameliorant.
Journal ArticleDOI
The possible role of endothelin-1 in the pathogenesis of coronary vasospasm.
Hiroki Kurihara,Masao Yoshizumi,Takao Sugiyama,Kazuhide Yamaoki,Ryozo Nagai,Fumimaro Takaku,Hiroyuki Satoh,Jun Inui,Masashi Yanagisawa,Tomoh Masaki,Yoshio Yazaki +10 more
TL;DR: It is suggested that ET-1, produced by vascular endothelial cells, may contribute to the regulation of coronary circulation and the pathogenesis of coronary vasospasm with respect to intimal injury and subsequent thrombus formation.
Patent
Pharmaceutical agent containing Rho kinase inhibitor
TL;DR: In this paper, a Rho kinase inhibitor is provided as a novel pharmaceutical agent, particularly as a therapeutic agent of hypertension, a therapeutic agents of angina pectoris, a suppressive agent of cerebrovascular contraction.
Patent
Benzamide compounds and pharmaceutical use thereof
Masafumi Arita,Tadamasa Yoshitomi Phar. Ind. Ltd. Saitoh,Masanori c,Hiroyuki Satoh,Hiroyuki Satoh +4 more
TL;DR: In this article, the authors present a compound of the formula "STR1" which has strong smooth muscle relaxing action, and shows hypotensive action and cerebral coronary vasodilating action like conventional calcium antagonists, as well as long-lasting renal and peripheral circulation improving action.